Drug Regulation India
3 articles on Drug Regulation India, written by Shotlee and medically reviewed for clinical accuracy.
India Cracks Down on GLP-1 Drug Misuse Amid Generic Surge
India's government is ramping up enforcement against GLP-1 drug misuse following a flood of cheap semaglutide generics. Inspections at 49 pharmacies, wholesalers, and clinics uncovered unauthorized sales and misleading marketing. With sales surging 177%, regulators warn of health risks without medical supervision.
5 min read
India Steps Up Oversight on GLP-1 Drugs Over Improper Practices
India's drug regulator is cracking down on GLP-1 weight loss drugs due to improper sales and promotions. Inspections across 49 entities revealed violations, leading to notices and potential license cancellations. With semaglutide generics now available post-patent expiry, authorities emphasize prescription-only use by specialists.
4 min read
Telangana DCA Warns Against Unsupervised Semaglutide Use Amid Weight Loss Demand
The Telangana Drugs Control Administration (DCA) has issued a strong warning against unsupervised use of semaglutide, a popular GLP-1 drug for weight loss and Type-2 diabetes management. With generics now available from Sun Pharma, Dr. Reddy's, Zydus, and Glenmark following patent expiry, demand is surging—but so are risks like acute pancreatitis and kidney injury. Always consult a doctor for proper assessment and prescription.
5 min read